# A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

> **NCT05247216** · PHASE2 · COMPLETED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 140 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Hemay007 800 mg QD group
- **DRUG:** Hemay007 1200 mg QD group
- **DRUG:** Hemay007 600 mg QD group
- **DRUG:** Hemay007 placebo group

## Key facts

- **NCT ID:** NCT05247216
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-26
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-06-22
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247216, "A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05247216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*